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About 9.6% of the Taiwan population are 65 years of age
or older1. By the year 2020, it is predicted that more
than 14% of the population will fall into this age range.
Osteoarthritis (OA) is the most common form of chronic
arthritis in the elderly in Taiwan; it is a major disease
associated with significant morbidity, and is one of the
most common causes of functional limitation and
dependency2–4. The prevalence of radiographic knee
OA is 42.8% in elderly Chinese women and 21.5% in
men5.Knee OA is particularly disabling due to symptoms
such as pain, stiffness, muscle weakness, and limited
range of motion (ROM)6. Furthermore, restricted joint
ROM is associated with abnormal posture and may
exacerbate disability. The age-related changes in muscle
strength and knee OA increase susceptibility to falls,
which are associated with significant morbidity and
mortality in the elderly7,8.
Risk Factors for Knee OA
OA is a slowly developing multifactorial disorder in
which aging, genetic, hormonal, and mechanical fac-
tors are major contributors to its onset and progres-
sion9,10. The incidence and prevalence of this disease
increase directly with age. By the age of 60 years, nearly
100% of the population will have histologic changes of
degeneration in their knee cartilage, over 80% will have
radiographic evidence of OA in at least 1 joint, about
40% will report having clinical symptoms of arthritis,
and about 10% will report activity limitation caused by
arthritis10. In an elderly cohort in the Framingham OA
study (age range, 63–94 years), radiographic knee OA
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was present in 27% of those below 70 years of age, and
44% in those aged 80 years or above11. Symptomatic
knee OA was less common than radiographic OA, with
7% of those below 70 years of age, and 11.2% of those 
80 years or above reporting knee pain on most days
for at least a month11. The rate of incident radio-
graphic OA of the knee was about 2% per year in
women, and progressive disease occurred at 4% per
year with approximately 1% per year developing new
knee pain11.
Previous studies have found that the female sex is
associated with an increased risk of OA12,13. At 50 years
of age, women have higher rates of incident knee OA
compared to men14, and a higher prevalence of radio-
graphic and symptomatic OA3,15,16. The Framingham
OA study showed that women had rates of incident
disease 1.7 times higher than that in men15. Recent
epidemiologic studies suggested that postmenopausal
estrogen deficiency could play a role in the develop-
ment of knee OA in older women17–19.
After age, obesity is the strongest modifiable risk
factor for the development of knee OA, particularly in
women10. For incident radiographic knee OA in the eld-
erly Framingham group, higher body mass index (BMI)
was associated with an odds ratio of 1.6 per 5-unit
increase in BMI20,21. Weight change also correlated with
risk such that an increase in risk of knee OA of 40%
was noted per 10-lb weight gain and a similar decrease
in risk was noted for weight loss. Among the elderly,
the combination of obesity and heavy physical activity
is associated with an enhanced risk of knee OA. Data
from the Framingham heart study showed that elderly
individuals in the upper tertile of BMI who performed
at least 3 hours of significant physical activity daily had
an odds ratio of 13 for developing knee OA22.
A prior history of knee injury is also a risk factor for
knee OA15,23,24. In a 21-year follow-up of 107 patients
who had undergone meniscectomy for management of
an isolated meniscus tear, the relative risk of develop-
ing radiographic knee OA compared with that of age-
and sex-matched controls was 1424. Recent studies have
also suggested that quadriceps weakness is associated
with radiographic and symptomatic knee OA in com-
munity-dwelling elderly individuals25. In addition,
knee proprioception declines with age, and muscle
weakness as well as reduced proprioception may con-
tribute to the development of knee OA. These factors
could certainly be expected to be involved in the effect
of knee OA on physical function26.
Pathobiology of OA
Pathologically, OA is characterized by fibrillation and
loss of articular cartilage, hypertrophic changes in the
neighboring bone including subchondral thickening
and osteophyte formation, some degree of synovial
change with patchy areas of synovitis and areas of
hypertrophy, and thickening of the joint capsule27.
The earliest changes involve roughening of the carti-
lage surface in areas of the knee joint that receive the
greatest stress, such as regions of the tibial condyles not
covered by the menisci and vertical ridge of the patella28.
The morphologic changes become more common and
more extensive with advancing age.
The pathobiology of OA is much more complicated
than either simple joint aging or wear and tear from
repetitive use. OA has traditionally been regarded as
noninflammatory arthritis, but improved detection
methods show that the inflammatory pathways are
upregulated29. OA results from articular cartilage failure
caused by a complex interplay of genetic, metabolic,
and biomechanical factors with secondary compo-
nents of synovitis. The increased catabolic activity is
caused by increased levels of several matrix metallopro-
teases (MMP), including MMP 1, 2, 8, 9, and 13, and the
newly discovered enzyme, aggrecanase30,31. Inadequate
repair of damaged matrix may be caused by age-related
increase in apoptosis32, decrease in mitogenic response
to insulin-like growth factor-I and other growth factor
stimulation with age33,34, and decline in proteoglycan
synthesis, which has been shown to be correlated with
an age-associated increase in pentosidine levels sug-
gesting accumulation of advanced glycation end prod-
ucts35. Cytokines and other signaling molecules released
from the cartilage, synovium, and bone affect chondro-
cyte function36. Levels of inflammatory cytokines such
as interleukin (IL)-1 are increased in OA cartilage and
are thought to be important in stimulating catabolism
and inhibiting anabolic processes37. Age-related changes
in the overall composition of the cartilage matrix also
result in a tissue that is less able to handle mechanical
stress.
Thickening of the subchondral bone, a consistent
finding in OA38,39, places additional stress on the over-
lying cartilage during joint loading resulting in mechan-
ical failure of the cartilage40. Multiple factors such as
body weight, joint stability, and muscle strength influ-
ence the rate at which age-related changes result in
the development and progression of OA.
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Clinical Manifestations of Knee OA
The principal symptom associated with knee OA is artic-
ular pain, which is typically exacerbated by activity and
relieved by rest41. In a more advanced stage of the dis-
ease, pain may be noted with progressively less activ-
ity, eventually occurring at rest and at night. Articular
pain is an important issue in the care of elderly peo-
ple, and perhaps the most important problem in their
daily lives. Morning stiffness is also a common com-
plaint in knee OA patients. It typically resolves less
than 30 minutes after patients awaken, but may recur
following periods of inactivity. Joint effusions may be
present, which typically exhibit a mild pleocytosis and
normal viscosity42. Limitation of ROM is a common sign
of knee OA41,42. In advanced cases, malalignment may
be apparent (genu varus or genu valgus), particularly
when medial and lateral compartments are affected
unequally. A fluctuant swelling along the posterior
aspect of the knee, or Baker’s cyst, is also a common
complication. The most common clinical problem is
differentiation of painful OA from other common causes
of regional or generalized joint pain in elderly people,
referred pain, periarticular (soft-tissue) conditions, and
somatization. The diagnosis of knee OA remains prima-
rily clinical, and the American College of Rheumatology
(ACR) has developed classification criteria for this dis-
ease to assist the clinician in identifying patients with
symptomatic OA43.
Management of Knee OA in 
Elderly Patients
The goals of management of elderly patients with knee
OA are to control articular pain and swelling, minimize
disability, improve the quality of life, prevent progres-
sion of the process, and educate the patient about
lifestyle modification. The initial plan for management
should be tailored to the individual patient but usually
includes nonpharmacologic modalities combined with
pharmacologic measures44.
Nonpharmacologic modalities
The ACR has recently developed guidelines for the
management of knee OA that stress the importance of
nonpharmacologic measures45. The multidisciplinary
team approach often used in geriatric medicine clearly
applies to managing elderly patients with knee OA44–46.
Epidemiologic studies suggested that obesity is strongly
associated with the development of elderly OA20–22, so
clinicians should encourage their obese patients with
knee OA to lose weight. Even moderate weight loss
may relieve joint pain, produce improvement in phys-
ical function, and reduce progression of OA. Patients
can be encouraged by the finding that an average 
10-lb weight loss reduced the risk of knee OA by almost
50% in the Framingham cohort47. To achieve weight loss
in older adults with knee OA, dietary intervention to
reduce caloric intake should be recommended.
Given the importance of muscle strength in the
pathogenesis of knee OA25, exercises to strengthen the
quadriceps are particularly important. Individualized
strengthening programs developed by therapists have
been shown to improve strength and function and
relieve pain in subjects with knee OA48. Studies have
shown that elderly subjects are capable of increasing
their quadriceps strength using weights49,50. If available,
weight-training equipment, such as a leg extension
machine, is beneficial since the weight can more easily
be controlled and advanced as the patient improves in
strength. In the Fitness and Arthritis Seniors Trial51, aero-
bic walking was compared with a low-level strength
training program with comparable results in terms of
relief of pain and improvement in physical function.
The optimal exercise plan may be a combination of
lower extremity strengthening exercises and aerobic
walking. However, several factors must be considered
when creating an individualized exercise program for
an elderly patient with knee OA. As an example, a rel-
atively high intensity aerobic exercise program should
not be employed for patients with moderate-to-severe
OA. The American Geriatrics Society, which supports exer-
cise for elderly OA, has released guidelines for exercise
regimens for such individuals52.
Patient education and psychosocial support have
been shown to relieve pain in OA patients53,54. Patient
education should include informative discussions of the
disease and of physical disability, therapeutic options,
and the risks and benefits of the different approaches
to management53. Institution of appropriate counsel-
ing and antidepressant therapy when indicated are also
important issues for the management of elderly patients
with knee OA55.
There is evidence that physical therapy improves
clinical outcome in knee OA56. Physical therapists help
by developing an exercise program, and occupational
therapists provide guidance in using assistant devices.
Physical modalities to improve function can be just as
important as those that relieve pain. The application of
warm or cold packs to the symptomatic joint can also be
helpful. Therapeutic ultrasound has been used to treat
knee OA, and is reputed to reduce edema, relieve pain,
increase ROM, and accelerate joint tissue repair57.
Finally, braces and splints may be useful for symp-
tomatic relief for those with knee OA. As an example,
valgus bracing of the knee not only reduces pain, but
also improves function in patients with OA of the knee
that predominantly affects the medial compartment58.
In patients with more advanced disease, assistive devices
such as a cane should be recommended.
Pharmacologic therapy
The focus in managing patients with knee OA should
not only be centered on pain relief but also on func-
tion improvement. When medications are needed, the
least toxic drugs should be used for older adults 
who have increased susceptibility to unwanted side
effects. Choices to this end include acetaminophen,
non-narcotic analgesics, nonsteroidal anti-inflammatory
drugs (NSAIDs), topical analgesics, intra-articular corti-
costeroids, and disease-modifying osteoarthritis drugs
(DMOADs).
Acetaminophen has been shown to be as effica-
cious as NSAIDs in many patients with knee OA59,60.
Given its better side effect profile, acetaminophen is a
good choice as an analgesic for OA patients, and is the
recommended first drug of choice in the ACR guide-
lines for the management of knee OA45,46, and in the
guidelines for management of chronic pain in older
adults from the American Geriatrics Society61. It is
important that patients are instructed to use the
proper dosage of acetaminophen, which is 1 g 3–4
times a day.
The new ACR guidelines include the non-NSAID anal-
gesic drug tramadol for the treatment of pain associ-
ated with knee OA46. Tramadol has a dual mechanism
of action, binding to the µ-opioid receptor and inhibit-
ing the reuptake of norepinephrine and serotonin62.
A recently developed drug, Ultracet (tramadol 37.5 mg/
acetaminophen 325 mg), is indicated for the short-term
management of acute pain in elderly knee OA63.
In older adults who are at increased risk of side
effects from NSAIDs, local treatments should be tried
before NSAIDs. Local treatments, including arthrocen-
tesis and corticosteroid injections, are effective for eld-
erly OA patients with synovitis64,65. A general guideline
is not to inject the same joint within 6 weeks of a pre-
vious injection or more than 3–4 times a year.
If simple analgesics and local treatments in com-
bination with nonpharmacologic agents have not 
provided adequate pain relief, then NSAIDs may be
prescribed44,46. Although widely used in the manage-
ment of OA, NSAIDs do not provide an obvious advan-
tage over the other types of analgesics but have greater
potential for causing serious side effects, particularly
in the elderly population66,67. Numerous studies have
documented the increased risk of gastrointestinal (GI)
ulceration, bleeding, and death in elderly NSAID
users66,67. Other potential problems from NSAIDs, which
appear more commonly in older adults, include dete-
rioration of renal function68 and central nervous sys-
tem (CNS) symptoms, such as confusion, headache, and
vertigo. Therefore, indomethacin should not be used
to treat older adults with OA because it may exert
deleterious effects on the cartilage matrix, seems to be
the most toxic of the available NSAIDs, and causes
more CNS symptoms than the other NSAIDs66. A new
class of NSAIDs, the selective COX-2 inhibitors, has less
GI toxicity than conventional NSAIDs and provide an
alternative choice for elderly patients with knee
OA69–72. A cost-effective analysis by Yen et al. showed
that among selective COX-2 inhibitors, celebrex was
found to be a more cost-effective or even cost-saving
strategy if the probability of serious GI complications
from conventional NSAIDs was considered73. However,
COX-2 inhibitors potentially cause vascular thrombosis
and heart failure in the elderly population74,75. In
patients with known cardiovascular disease or those
with multiple risk factors for coronary heart disease,
COX-2 inhibitors should be reduced in dosage and
duration, or even be avoided. Since the symptoms of
knee OA are often intermittent, physicians should try to
discontinue NSAIDs when the patient’s symptoms have
been stably quiescent. Nonpharmacologic modalities,
such as exercise and weight reduction, should be 
continued.
Topical NSAIDs offer efficacy similar to that of orally
administered NSAIDs, reducing some aspects of GI and
renal toxicity. However, the efficacy of topical NSAIDs
appears to be of relatively short duration. A 2004 meta-
analysis, which included 13 trials involving almost 2,000
patients, showed a significant short-term (1–2 weeks)
efficacy of topical NSAIDs for pain relief and functional
improvement compared to that of placebo76. Topical
usage of capsaicin (which exerts its therapeutic effect
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by enhancing the release of substance P from unmyeli-
nated C nerve fibers) is recommended for patients who
do not respond to analgesics or who do not wish to
take systemic therapy77.
Disease- or structure-modifying osteoarthritis
drugs (DMOADs)
New therapeutic strategies for treating OA based on
present knowledge of its pathogenesis are evolving and
a new class of antiarthritis agents, known as DMOADs,
has been defined78. Clinical research studies are cur-
rently underway using other pharmacologic agents that
have been shown to favorably slow the disease process
in OA.
Tetracyclines have a variety of anti-inflammatory
effects that are mediated by inactivation of MMPs,
including collagenases, stromelysins, and gelatinases,
which degrade all components of the articular extra-
cellular matrix and can cause destruction of articular
cartilage79. Doxycycline may slow the rate of OA pro-
gression. A study showed that the rate of joint space
narrowing was significantly less in those treated with
doxycycline than in the placebo group79,80.
Glucosamine is important for the repair and main-
tenance of cartilage. A recent in vitro study provided
evidence that glucosamine could potentially inhibit
the activity of aggrecanase, which is responsible for
the cleavage of the large aggregating proteoglycan in
cartilage81. A 2005 meta-analysis of 20 controlled trials
of glucosamine including a total of 2,570 patients with
OA82 showed that a significant advantage over placebo
was noted in the efficacy of glucosamine for pain relief
and functional improvement, and there was a modest
benefit of glucosamine sulfate on slowing the rate of
joint space narrowing. However, a post hoc analysis did
not show any significant correlation between the degree
of pain relief and the change in joint space width. For
patients whose symptoms improve with glucosamine,
there is some evidence to suggest that regular use for
more than 6 months is no more effective in controlling
symptoms of OA than placebo. Adverse effects of glu-
cosamine are not significantly greater than for placebo,
but glucosamine should not be administered to patients
who are allergic to shellfish.
Chondroitin sulfate is composed of repeating units
of galactosamine sulfate and glucuronic acid. It is the
predominant glycosaminoglycan found in articular car-
tilage. A 2003 meta-analysis that involved 755 patients
with OA of the knee who were randomly assigned to
receive chondroitin sulfate or placebo showed that a
significant advantage over placebo was noted in the
efficacy of chondroitin sulfate for pain relief83. Some tri-
als also had a glucosamine arm, which showed that
the efficacy of chondroitin sulfate was similar to that
of glucosamine84. Despite the promising results noted
above, a large double-blind, placebo-controlled ran-
domized trial showed no significant difference in pain
relief between those receiving chondroitin sulfate alone
or the combination of glucosamine and chondroitin
sulfate and those receiving selective COX-2 inhibitor
(celecoxib)84.
Diacerein is metabolized to rhein, an agent that has
anti-inflammatory and analgesic properties85. An in vitro
study of cultured chondrocytes showed that rhein stim-
ulated prostaglandin E2 synthesis while inhibiting pro-
duction of IL-1β86,87. A 2006 systematic review of 7
clinical trials that included 2,069 patients with knee
OA noted a clinically modest pain relief compared to
placebo88. Diarrhea was a frequent adverse effect and
was reported in those taking diacerein. Another ther-
apy that has been found to relieve pain in knee OA is
avocado and soya unsaponifiables (ASU)89. They are
supposed to stimulate repair of extracellular matrix
components, thus enhancing the expression of trans-
forming growth factors β1 and β2 in cultured articular
chondrocytes. The majority of trial data available to date
suggest that ASU is effective for the symptomatic treat-
ment of OA90. However, the only real long-term trial
yielded a largely negative result.
Hyaluronic acid (HA), a major component of syno-
vial fluid (SF) and cartilage, is a high molecular weight
polysaccharide made of long nonsulfated straight
chains of variable disaccharide lengths composed of
N-acetylglucosamine and glucuronic acid. Its unique vis-
coelastic properties confer remarkable shock-absorbing
and lubricating abilities to SF91. In addition, HA can form
a pericellular coat around cells, interact with proin-
flammatory mediators, and bind to cell receptors to
modulate cell proliferation and migration91,92. It is now
believed that biologic activation of multiple protective
mechanisms may explain the long-term clinical bene-
fits. A 2005 meta-analysis showed a statistically signifi-
cant advantage for intra-articular HA injection in rest
pain between 2 and 6 weeks when compared to the
placebo group93,94. Recently, the ACR guidelines have
been updated to include recommendations for the use
of intra-articular hyaluronans46. However, there was no
statistically significant difference between those who
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received HA injections and those who received oral
NSAID (naproxen)93. Considering the limited resources
available for health care in Taiwan, intra-articular HA
treatment may not be an economical choice73.
When patients with symptomatic knee OA have failed
to respond to nonpharmacologic and pharmacologic
treatment approaches, surgery should be considered.
For those with severe knee OA, joint replacement is very
effective95.
Conclusion
Knee OA is a common and debilitating condition asso-
ciated with pain and loss of mobility that undermines
quality of life in the elderly population. Our under-
standing of the etiopathophysiology of knee OA has
grown significantly in recent decades, which has led to
targeted and more effective approaches to disease
management. Therapeutic advances include the intro-
duction of safer agents for symptomatic relief, as well as
agents with potential for disease (structure) modification.
Maintaining or restoring functional capacity in elderly
knee OA is an important public health issue. Cartilage
replacement by bone marrow stem cells and implan-
tation of autologous chondrocytes or bioengineered
tissues continue as important areas of therapeutic
interest.
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